SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 5.2% Stake in Acadia Pharmaceuticals
Beneficial Ownership Report
Investment firm RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a beneficial ownership of 5.2% in Acadia Pharmaceuticals Inc., totaling 8,705,501 shares.
Summary
- RTW Investments, LP and Roderick Wong, M.D. have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Acadia Pharmaceuticals Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 8,705,501 shares of Acadia Pharmaceuticals Inc. Common Stock.
- This ownership represents 5.2% of the company's outstanding Common Stock.
- The percentage is calculated based on 166,391,891 shares outstanding as of October 29, 2024, as reported in Acadia's Quarterly Report on Form 10-Q filed on November 7, 2024.
- Both RTW Investments, LP and Dr. Wong share voting and dispositive power over all 8,705,501 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or future prospects. It is a routine regulatory filing.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant passive investment by RTW Investments, LP, a healthcare-focused investment firm, and its managing partner, in Acadia Pharmaceuticals. Such disclosures are standard for institutional investors crossing the 5% ownership threshold and typically signal a long-term investment interest rather than an activist stance, as certified by the filers.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, which can be viewed as a vote of confidence or simply as a disclosure of a large holder.
Key Dates
| Date | Description |
|---|---|
| 2024-10-29 | Date of shares outstanding calculation (166,391,891 shares) as reported in the Company's Form 10-Q. |
| 2024-12-31 | Date of event which requires filing of this statement, representing the beneficial ownership stake. |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
Acadia Pharmaceuticals, RTW Investments, Roderick Wong, Schedule 13G, beneficial ownership, common stock, investment, pharmaceutical, biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.